Novel biaryl oxazolidinones: in vitro and in vivo activities with pharmacokinetics in an animal model

International Journal of Antimicrobial Agents

Volumn 33, Issue 3, 2009, Pages 280-284

  Barman, Tarani Kanta ^a   Pandya, Manisha ^a   Mathur, Tarun ^a   Bhadauriya, Tripti ^a   Rao, Madhvi ^a   Khan, Seema ^a   Singhal, Smita ^a   Bhateja, Pragya ^a   Sood, Ruchi ^a   Malhotra, Sunita ^a   Das, Biswajit ^a   Paliwal, Jyoti ^a   Bhatnagar, Pradip Kumar ^a   Upadhyay, Dilip J ^a  

^a RANBAXY RESEARCH LABORATORIES   (India)

Author keywords

Animal model; Linezolid resistant; MRSA; Oxazolidinone

Indexed keywords

LINEZOLID; OXAZOLIDINEDIONE DERIVATIVE; RBX 1000075; RBX 1000276; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBACTERIAL ACTIVITY; ARTICLE; BACTERIUM ISOLATION; BODY WEIGHT; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG SENSITIVITY; ENTEROCOCCUS; FEMALE; GRAM POSITIVE BACTERIUM; HALF LIFE TIME; INFECTION; LUNG INFECTION; MALE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; MORAXELLA CATARRHALIS; NONHUMAN; PHARMACOKINETICS; PRIORITY JOURNAL; RAT; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS EPIDERMIDIS; STREPTOCOCCUS PNEUMONIA; STREPTOCOCCUS PYOGENES; SURVIVAL;

ADMINISTRATION, ORAL; ANIMALS; ANTI-BACTERIAL AGENTS; GRAM-NEGATIVE BACTERIA; GRAM-POSITIVE BACTERIA; HALF-LIFE; MICE; MICROBIAL SENSITIVITY TESTS; OXAZOLIDINONES; PNEUMONIA, BACTERIAL; SEPSIS; SURVIVAL ANALYSIS;

EID: 60249096317     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2008.08.025     Document Type: Article

References (14)

1. Hiramatsu K. The emergence of Staphylococcus aureus with reduced susceptibility to vancomycin in Japan. Am J Med 104 (1998) 7S-10S
2. Nichols R.L. Optimal treatment of complicated skin and soft tissue infections. J Antimicrob Chemother 44 (1999) 19-23
3. Voss A.D., Milatovic D., Wallrauch-Schwarz C., Rosdahl V.T., and Braveny I. Methicillin-resistant Staphylococcus aureus in Europe. Eur J Clin Microbiol Infect Dis 13 (1994) 50-55
4. Appelbaum P.C. Antimicrobial resistance in Streptococcus pneumoniae: an overview. Clin Infect Dis 15 (1992) 77-83
5. Friedland I.R., and McCracken Jr. G.H. Management of infections caused by antibiotic-resistant Streptococcus pneumoniae. N Engl J Med 331 (1994) 377-382
6. Jacobs M.R., Bajaksouzian S., Zilles A., Lin G., Pankuch G.A., and Appelbaum P.C. Susceptibilities of Streptococcus pneumoniae and Haemophilus influenzae to 10 oral antimicrobial agents based on pharmacodynamic parameters: 1997 US surveillance study. Antimicrob Agents Chemother 43 (1999) 1901-1908
7. Perry C.M., and Jarvis B. Linezolid: a review of its use in the management of serious Gram-positive infections. Drugs 6 (2001) 525-551
8. Attassi K., Hershberger E., Alam R., and Zervos M.J. Thrombocytopenia associated with linezolid therapy. Clin Infect Dis 34 (2002) 695-698
9. Green S.L., Maddox J.C., and Huttenbach E.D. Linezolid and reversible myelosuppression. J Am Med Assoc 285 (2001) 1291-1293
10. Wilson P., Andrews J.A., Charlesworth R., Walesby R., Singer M., Farrell D.J., et al. Linezolid resistance in clinical isolates of Staphylococcus aureus. J Antimicrob Chemother 51 (2003) 186-188
11. Clinical and Laboratory Standards Institute. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Approved standard. M7-A7 (2006), CLSI, Wayne, PA
12. Finney D.J. Statistical methods in biological assay. 2nd ed. (1971), Charles Griffin, London, UK p. 524-30
13. Dibo I., Pillai S.K., Gold H.S., Baer M.R., Wetzler M., Snack J.L., et al. Linezolid-resistant Enterococcus faecalis isolated from a cord blood transplant recipient. J Clin Microbiol 42 (2004) 1843-1845
14. Michel M., and Gutmann L. Methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococci: therapeutic realities and possibilities. Lancet 349 (1997) 1901-1906